Literature DB >> 18374908

Nicotine and caffeine-mediated modulation in the expression of toxicant responsive genes and vesicular monoamine transporter-2 in 1-methyl 4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease phenotype in mouse.

Seema Singh1, Kavita Singh, Suman Patel, Devendra Kumar Patel, Chetna Singh, Chandishwar Nath, Mahendra Pratap Singh.   

Abstract

Epidemiological evidence revealed that cigarette smokers and coffee drinkers have lower risk of Parkinson's disease (PD). Nicotine inhibits monoamine oxidase activity, and induces expression of neurotrophic factors and nicotinic acetylcholinergic receptors. However, caffeine is capable of antagonizing adenosine A(2A) receptor. Toxicant responsive enzymes and vesicular monoamine transporter-2 (VMAT-2) play critical roles in chemically induced PD. Despite some known functions, the effects of nicotine and caffeine on the expression and activity of toxicant responsive genes and on VMAT-2 are still not known. The study was therefore undertaken to investigate the effect of nicotine and caffeine on the expression and activity of toxicant responsive genes, i.e., CYP1A1, CYP2E1, GST-ya, GST-yc, GSTA4-4 and VMAT-2 in the striatum of control and MPTP-induced PD phenotype in mouse. The animals were treated intraperitoneally daily with nicotine (1 mg/kg) or caffeine (20 mg/kg) for 8 weeks, followed by 1-methyl 4-phenyl-1,2,3,6-tetrahydropyridine (MPTP; 20 mg/kg)+nicotine or caffeine for 4 weeks. MPTP significantly attenuated CYP1A1 and VMAT-2, and augmented CYP2E1, GST-ya, GST-yc and GSTA4-4 expression/activity. Nicotine or caffeine-treated animals showed significant restoration against most of the MPTP-induced alterations. The results obtained thus suggest that nicotine and caffeine modulate MPTP-induced alterations in CYP1A1, CYP2E1, GST-ya, GST-yc, GSTA4-4 and VMAT-2 expression/activity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18374908     DOI: 10.1016/j.brainres.2008.02.023

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  9 in total

1.  The Therapeutic Implications of Tea Polyphenols Against Dopamine (DA) Neuron Degeneration in Parkinson's Disease (PD).

Authors:  Zhi Dong Zhou; Shao Ping Xie; Wuan Ting Saw; Patrick Ghim Hoe Ho; Hongyan Wang; Zhou Lei; Zhao Yi; Eng King Tan
Journal:  Cells       Date:  2019-08-16       Impact factor: 6.600

2.  Effect of nicotine on cytochrome P450 1A2 activity.

Authors:  Janne Hukkanen; Peyton Jacob; Margaret Peng; Delia Dempsey; Neal L Benowitz
Journal:  Br J Clin Pharmacol       Date:  2011-11       Impact factor: 4.335

3.  Single and combined effects of selected pharmaceuticals at sublethal concentrations on multiple biomarkers in Carassius auratus.

Authors:  Zhihua Li; Guanghua Lu; Xiaofan Yang; Chao Wang
Journal:  Ecotoxicology       Date:  2011-09-24       Impact factor: 2.823

4.  Role of secondary mediators in caffeine-mediated neuroprotection in maneb- and paraquat-induced Parkinson's disease phenotype in the mouse.

Authors:  Sharawan Yadav; Satya Prakash Gupta; Garima Srivastava; Pramod Kumar Srivastava; Mahendra Pratap Singh
Journal:  Neurochem Res       Date:  2011-12-27       Impact factor: 3.996

5.  Minocycline Rescues from Zinc-Induced Nigrostriatal Dopaminergic Neurodegeneration: Biochemical and Molecular Interventions.

Authors:  Vinod Kumar; Brajesh Kumar Singh; Amit Kumar Chauhan; Deepali Singh; Devendra Kumar Patel; Chetna Singh
Journal:  Mol Neurobiol       Date:  2015-03-13       Impact factor: 5.590

6.  Nicotinic acetylcholine receptor availability in cigarette smokers: effect of heavy caffeine or marijuana use.

Authors:  Arthur L Brody; Robert Hubert; Michael S Mamoun; Ryutaro Enoki; Lizette Y Garcia; Paul Abraham; Paulina Young; Mark A Mandelkern
Journal:  Psychopharmacology (Berl)       Date:  2016-07-01       Impact factor: 4.530

7.  The promise of neuroprotective agents in Parkinson's disease.

Authors:  Stacey E Seidl; Judith A Potashkin
Journal:  Front Neurol       Date:  2011-11-21       Impact factor: 4.003

Review 8.  Caffeine: An Overview of Its Beneficial Effects in Experimental Models and Clinical Trials of Parkinson's Disease.

Authors:  Giovanni Schepici; Serena Silvestro; Placido Bramanti; Emanuela Mazzon
Journal:  Int J Mol Sci       Date:  2020-07-04       Impact factor: 5.923

Review 9.  Addressing the Neuroprotective Actions of Coffee in Parkinson's Disease: An Emerging Nutrigenomic Analysis.

Authors:  Lai Kuan Lee; Nur Anis Raihana Mhd Rodzi
Journal:  Antioxidants (Basel)       Date:  2022-08-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.